Medifast (MED) Liabilities and Shareholders Equity (2010 - 2026)

Medifast has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $252.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 9.99% year-over-year to $252.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (down 9.7% YoY), and the FY2025 full-year result was $248.0 million, down 12.75% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $252.0 million, up from $248.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $421.4 million in Q1 2022, with the low at $248.0 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $303.8 million across 5 years, with a median of $302.8 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity increased 29.12% — and 2023, when it dropped 23.69%.
• Medifast's Liabilities and Shareholders Equity stood at $316.2 million in 2022, then slipped by 1.99% to $309.9 million in 2023, then declined by 8.29% to $284.2 million in 2024, then dropped by 12.75% to $248.0 million in 2025, then gained by 1.64% to $252.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $252.0 million (Q1 2026), $248.0 million (Q4 2025), and $268.2 million (Q3 2025), per Business Quant data.